Attached files
file | filename |
---|---|
10-K - FORM 10-K - ANADYS PHARMACEUTICALS INC | a58867e10vk.htm |
EX-32.1 - EX-32.1 - ANADYS PHARMACEUTICALS INC | a58867exv32w1.htm |
EX-31.2 - EX-31.2 - ANADYS PHARMACEUTICALS INC | a58867exv31w2.htm |
EX-31.1 - EX-31.1 - ANADYS PHARMACEUTICALS INC | a58867exv31w1.htm |
EX-10.21 - EX-10.21 - ANADYS PHARMACEUTICALS INC | a58867exv10w21.htm |
EX-10.19 - EX-10.19 - ANADYS PHARMACEUTICALS INC | a58867exv10w19.htm |
EX-10.23 - EX-10.23 - ANADYS PHARMACEUTICALS INC | a58867exv10w23.htm |
EX-10.20 - EX-10.20 - ANADYS PHARMACEUTICALS INC | a58867exv10w20.htm |
EX-10.22 - EX-10.22 - ANADYS PHARMACEUTICALS INC | a58867exv10w22.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-8 (No.s
333-113954, 333-120647, 333-129716, 333-137114, 333-145889, 333-154743, 333-162776 and 333-170486)
and Form S-3 (No.s 333-124231, 333-132729, 333-158342 and 333-171414) of Anadys Pharmaceuticals,
Inc. and in the related Prospectus, of our reports dated March 4, 2011, with respect to the
consolidated financial statements of Anadys Pharmaceuticals, Inc., and the effectiveness of
internal control over financial reporting of Anadys Pharmaceuticals, Inc., included in this Annual
Report (Form 10-K) for the year ended December 31, 2010.
/s/ Ernst & Young LLP | ||||
San Diego, California
March 4, 2011
March 4, 2011